Tympner F, Reiner T, Domschke W
Fortschr Med. 1977 Jul 21;95(27):1711-4.
Fecal chymotrypsin determination and secretin-pancreozymin test with volume-loss corrected were carried out intra-individually on 57 clinically normal test subjects and 51 patients with chronic pancreatic disease. A good correlation could be established in every case between the chymotrypsin activity in stool and the chymotrypsin output in the duodenal aspirate. False-positive chymotrypsin activity was not to be found in healthy subjects. On the other hand, however, the chymotrypsin activity in stool compared with the result of the secretin-pancreozymin test was found to be false negative in 21% of all patients with chronic pancreatic disease (some or all parameters pathological). In patients with a clear deficiency in the exocrine function of pancreas (all parameters pathological) the chymotrypsin activity was nevertheless seen to be false-negative in only 9.9% of the cases. Thus the fecal chymotrypsin determination can be used as screening test for the clearly reduced pancreatic exocrine insufficiency.
对57名临床正常的受试者和51名慢性胰腺疾病患者进行了粪便糜蛋白酶测定以及校正失液量后的促胰液素-胰酶泌素试验。在每一例中,粪便中的糜蛋白酶活性与十二指肠抽吸物中的糜蛋白酶分泌量之间均能建立良好的相关性。健康受试者中未发现假阳性的糜蛋白酶活性。然而,另一方面,在所有慢性胰腺疾病患者(部分或全部参数异常)中,发现与促胰液素-胰酶泌素试验结果相比,粪便中的糜蛋白酶活性有21%为假阴性。在胰腺外分泌功能明显不足(所有参数异常)的患者中,糜蛋白酶活性仅在9.9%的病例中为假阴性。因此,粪便糜蛋白酶测定可作为胰腺外分泌功能明显降低的筛查试验。